Olaparib +/- Cediranib or Chemotherapy in Patients With Platinum-resistant Ovarian Cancer
Status:
Active, not recruiting
Trial end date:
2021-11-30
Target enrollment:
Participant gender:
Summary
The trial will compare the drugs olaparib and cediranib with standard chemotherapy in
platinum resistant ovarian cancer. Patients will be randomised to one of three treatment
groups: olaparib only, olaparib and cediranib and the control group paclitaxel. The aim is to
compare efficacy of the 3 treatments and also how well each treatment is tolerated including
the participants quality of life.